Ionis Pharmaceuticals (IONS) Amortization of Deferred Charges (2013 - 2026)

Ionis Pharmaceuticals' Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $3.5 million for Q2 2026.

• In Q2 2026, Amortization of Deferred Charges rose 35.33% year-over-year to $3.5 million; the TTM figure through Jun 2026 stood at $12.1 million (up 17.54% YoY), while the FY2025 annual figure was $10.2 million, up 2.06% from the prior year.
• Amortization of Deferred Charges for Q2 2026 stood at $3.5 million, up from $3.5 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $3.5 million in Q2 2026, with the low at $1.3 million in Q4 2022.
• The 5-year median for Amortization of Deferred Charges is $2.4 million (2023), against an average of $2.3 million.
• The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges jumped 80.74% in 2023, then plunged 35.35% in 2025.
• Ionis Pharmaceuticals' Amortization of Deferred Charges stood at $1.3 million in 2022, then soared by 80.34% to $2.4 million in 2023, then increased by 6.42% to $2.6 million in 2024, then jumped by 34.11% to $3.4 million in 2025, then climbed by 1.77% to $3.5 million in 2026.
• Business Quant data shows IONS's Amortization of Deferred Charges at $3.5 million in Q2 2026, $3.5 million in Q1 2026, and $3.4 million in Q4 2025.